NasdaqGM:ZLAB

Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List

Retrieved on: 
Wednesday, December 13, 2023
Food, ABSSSI, Bronchopneumonia, NMPA, Public, NRDL, Patient, Safety, CABP, Pharmaceutical industry

Earlier this year, NHSA added the intravenous (IV) formulation of NUZYRA to the NRDL for the treatment of CABP and ABSSSI.

Key Points: 
  • Earlier this year, NHSA added the intravenous (IV) formulation of NUZYRA to the NRDL for the treatment of CABP and ABSSSI.
  • “The addition of oral NUZYRA to China’s NRDL allows millions of patients increased accessibility, at reduced prices, to the once-daily oral and IV formulations of this life-saving therapy for serious community-acquired infections,” said Evan Loh, M.D., Paratek chief executive officer.
  • “This inclusion further expands China’s antibiotic armamentarium to address antimicrobial resistance, an ever-growing, urgent, global public health crisis.
  • Paratek’s partner in China, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), received approval of both IV and oral NUZYRA as a Category 1 innovative drug by the National Medical Products Administration (NMPA) of China for the treatment of CABP and ABSSSI in December 2021.

Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Bowlero, and Chegg and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, August 7, 2023
P.C, CHGG, ChatGPT, NSCLC, Holding Foreign Companies Accountable Act, Patient, Holding, News, NYSE, Cryptocurrency, Audit, Pharmaceutical industry, Bowlero Corporation, Chegg

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Zai Lab and the other companies named in the SEC notification have until March 29, 2022 to challenge the charges against them.
  • On this news, Zai Lab's stock price fell $6.74 per share, or 18%, to close at $30.02 per share on March 10, 2022.
  • Then, on May 1, 2023, Chegg held a conference call to discuss its results for the first quarter of 2023.

Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 27, 2023
P.C, Franchise Group, Adalimumab, FRG, NSCLC, Holding Foreign Companies Accountable Act, Geisler, Patient, Holding, CRL, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, House, News, NYSE, BLA, Food, Cryptocurrency, Audit

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Xponential purports to be the largest global franchisor of boutique fitness brands and went public on July 21, 2021 at $12.00 per share.
  • On April 6, 2022, an entity affiliated with Xponential's Chairman of the Board sold 5.175M shares at $20.00 per share in a secondary offering.
  • Zai Lab and the other companies named in the SEC notification have until March 29, 2022 to challenge the charges against them.

Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, July 22, 2023
P.C, Franchise Group, Adalimumab, FRG, NSCLC, Holding Foreign Companies Accountable Act, Geisler, Patient, Holding, CRL, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, House, News, NYSE, BLA, Food, Cryptocurrency, Audit

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Xponential purports to be the largest global franchisor of boutique fitness brands and went public on July 21, 2021 at $12.00 per share.
  • On April 6, 2022, an entity affiliated with Xponential's Chairman of the Board sold 5.175M shares at $20.00 per share in a secondary offering.
  • Zai Lab and the other companies named in the SEC notification have until March 29, 2022 to challenge the charges against them.

Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, July 17, 2023
P.C, Franchise Group, Adalimumab, FRG, NSCLC, Holding Foreign Companies Accountable Act, Geisler, Patient, Holding, CRL, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, House, News, NYSE, BLA, Food, Cryptocurrency, Audit

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Xponential purports to be the largest global franchisor of boutique fitness brands and went public on July 21, 2021 at $12.00 per share.
  • On April 6, 2022, an entity affiliated with Xponential's Chairman of the Board sold 5.175M shares at $20.00 per share in a secondary offering.
  • Zai Lab and the other companies named in the SEC notification have until March 29, 2022 to challenge the charges against them.

Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, July 11, 2023
P.C, Franchise Group, Adalimumab, FRG, NSCLC, Holding Foreign Companies Accountable Act, Geisler, Patient, Holding, CRL, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, House, News, NYSE, BLA, Food, Cryptocurrency, Audit

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Xponential purports to be the largest global franchisor of boutique fitness brands and went public on July 21, 2021 at $12.00 per share.
  • On April 6, 2022, an entity affiliated with Xponential's Chairman of the Board sold 5.175M shares at $20.00 per share in a secondary offering.
  • Zai Lab and the other companies named in the SEC notification have until March 29, 2022 to challenge the charges against them.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

Retrieved on: 
Sunday, July 9, 2023
NSCLC, Patient, Pomerantz, News, Cryptocurrency

NEW YORK, July 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB).

Key Points: 
  • NEW YORK, July 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB).
  • The investigation concerns whether Zai Lab and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On June 6, 2023, Zai Lab reported phase 3 trials for an oncology therapy it is developing with the oncology company NovoCure.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 6, 2023
P.C, Franchise Group, Adalimumab, NSCLC, Holding Foreign Companies Accountable Act, Geisler, Patient, Holding, CRL, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, House, News, NYSE, BLA, Food, Cryptocurrency, Audit

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Xponential purports to be the largest global franchisor of boutique fitness brands and went public on July 21, 2021 at $12.00 per share.
  • On April 6, 2022, an entity affiliated with Xponential's Chairman of the Board sold 5.175M shares at $20.00 per share in a secondary offering.
  • Zai Lab and the other companies named in the SEC notification have until March 29, 2022 to challenge the charges against them.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

Retrieved on: 
Sunday, July 2, 2023
NSCLC, Patient, Pomerantz, News, Cryptocurrency

NEW YORK, July 02, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB).

Key Points: 
  • NEW YORK, July 02, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB).
  • The investigation concerns whether Zai Lab and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On June 6, 2023, Zai Lab reported phase 3 trials for an oncology therapy it is developing with the oncology company NovoCure.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation – ZLAB

Retrieved on: 
Saturday, July 1, 2023
Titan, NSCLC, Patient, Advertising, News, I-Space (Chinese company), Cryptocurrency

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=16923 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.